



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.
Phone : +91 92280 16100 - 03 | +91 79 2646 8353 | Fax : +91 79 26404961
Regd. Office & Factory : 179/1, Vasna-lyava, Tal. Sanand, Dist. : Ahmedabad.
E-mail : info@ishitadrugs.com | ishitadrugs@vsnl.net | URL : www.ishitadrugs.com



Date: 13th November, 2017

To,
The Company Section
The Bombay Stock Exchange
Phiroz Jijibhoy Towers
Dalal Street, Bombay- 400 001

Security Code: 524400

Dear Sir,

Sub: Outcome of Board Meeting held on 13th November, 2017 pursuant to Regulation 30 of SEBI (LODR) Regulation, 2015.

This is to inform you that the Board of directors of the Company at its meeting held today on Monday, the 13th Day of November, 2017 have

1. Approved the Unaudited Financial Results of the Company along with the Limited Review Report for the quarter and half year ended on 30th September, 2017 pursuant to Regulation 33 of SEBI (LODR) Regulation, 2015.

Hope the enclosed papers are in accordance with requirements. Please take the same on your records and oblige. Please do the needful.

Thanking You.

For, Ishita Drugs & Industries Ltd.


Authorized Signatory



"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054
D & B D-U-N-S Number - 65-018-0359

ISHITA DRUGS AND INDUSTRIES LIMITED
 CIN: L24231GJ1992PLC017054
 Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
 Ahmedabad - 382170
 Website: www.ishitadrugs.com
 Contact: +91 9228016100

Unaudited Financial Results for the Quarter and Half year Ended September 30, 2017

Amount in Lacs except Per Share data

Particulars	Quarter Ended			Half Year Ended		Year Ended
	3 Months Ended	3 Months Ended	3 Months Ended	6 Months Ended	6 Months Ended	12 Months Ended
	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
	30-Sep-17	30-Jun-17	30-Sep-16	30-Sep-17	30-Sep-16	31-Mar-17
1 INCOME						
Revenue from Operations	194.54	141.22	91.68	335.76	249.63	640.04
Other Income	5.07	-2.91	2.86	2.16	5.38	12.02
Total Income	199.61	138.31	94.54	337.92	255.01	652.06
2 EXPENSES						
(a) Cost of Material Consumed	119.09	75.87	46.85	194.97	147.71	369.02
(b) Purchase of Stock-In-Trade	9.28	0	1.34	9.28	10.07	15.47
(c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	18.37	-4.42	-7.84	13.95	-10.63	12.74
(d) Employee Benefit Expense	19.96	19.92	16.58	39.87	31.96	69.17
(e) Finance Cost	0.55	0.94	0.63	1.49	1.12	4.46
(f) Depreciation, Depletion and Amortisation Expense	3.00	4.00	3.85	7.00	7.71	13.99
(g) Other Expense	22.49	35.12	29.00	57.60	58.46	141.51
Total Other Expenses	22.49	35.12	29.00	57.60	58.46	141.51
Total Expenses	192.74	131.43	90.41	324.16	246.40	626.36
3 Total Profit before Exceptional Items and Tax	6.87	6.88	4.13	13.76	8.61	25.70
4 Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
5 Total Profit before Tax	6.87	6.88	4.13	13.76	8.61	25.70
6 Tax Expense						
7 Current Tax	1.71	1.89	1.14	3.60	2.14	7.46
8 Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
9 Total Tax Expenses	1.71	1.89	1.14	3.60	2.14	7.46
10 Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00
11 Net Profit Loss for the period from continuing operations	5.16	5.00	3.00	10.16	6.47	18.25
12 Profit / (Loss) from discontinued operations before tax	0.00	0.00	0.00	0.00	0.00	0.00
13 Tax Expenses of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
14 Net Profit / (Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00	0.00	0.00
15 Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00	0.00
16 Total Profit / (Loss) for the period	5.16	5.00	3.00	10.16	6.47	18.25

Handwritten signature



17	Other Comprehensive Income net of Taxes	0.00	0.00	0.00	0.00	0.00	0.00
18	Total Comprehensive Income for the Period	5.16	5.00	3.00	10.16	6.47	18.25
19	Total profit or loss attributable to						
	Profit or loss, attributable to owners of parents	0.00	0.00	0.00	0.00	0.00	0.00
	Total Profit or loss, attributable to non-controlling interests	0.00	0.00	0.00	0.00	0.00	0.00
20	Total comprehensive income for the period attributable to						
	Comprehensive income for the period attributable to the owners of parents	0.00	0.00	0.00	0.00	0.00	0.00
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests	0.00	0.00	0.00	0.00	0.00	0.00
21	Details of Equity Share Capital						
	Paid-Up Equity Share Capital	299.03	299.03	299.03	299.03	299.03	299.03
	Face Value of Equity Share Capital	10	10	10	10	10	10
22	Details of Debt Securities						
	Paid-Up Debt Capital	0.00	0.00	0.00	0.00	0.00	0.00
	Face Value of Debt Securities	0.00	0.00	0.00	0.00	0.00	0.00
23	Reserves Excluding Revaluation Reserves	0.00	0.00	0.00	294.29	0.00	282.43
24	Debenture Redemption Reserve	0.00	0.00	0.00	0.00	0.00	0.00
25	Earnings Per Share						
(i)	Earnings Per Share for continuing operations						
	Basic Earnings / (Loss) per share from continuing operations	0.17	0.17	0.10	0.34	0.22	0.61
	Diluted Earnings / (Loss) per share from continuing operations	0.17	0.17	0.10	0.34	0.22	0.61
(ii)	Earnings Per Share for discontinued operations						
	Basic Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
	Diluted Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
(iii)	Earnings per Equity Share						
	Basic Earnings / (Loss) per share from continuing and discontinued operations	0.17	0.17	0.10	0.34	0.22	0.61
	Diluted Earnings / (Loss) per share from continuing and discontinued operations	0.17	0.17	0.10	0.34	0.22	0.61
26	Debt Equity Ratio*	0		0	0	0	0
27	Debt Service Coverage Ratio*	0		0	0	0	0
28	Interest Service Coverage Ratio*	0		0	0	0	0
	* The Company has no long term debt as on date						

The Company adopted Indian Accounting Standards (IndAS) from April 1, 2017 as per road map released by Ministry of Corporate Affairs (MCA). Reconciliation of

Net Profit after tax as previously reported under Indian GAAP and IndAS for the quarter ended September 30, 2016 is as follows:

Description	Quarter ended	Half Year ended
	30-Sep-16	30-Sep-16
	Unaudited	Unaudited
Net Profit as per Previous Indian GAAP	3.00	6.47
Net Profit as per IndAS	3.00	6.47

NOTES

- The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on November 13, 2017.
- The Limited Review of the results has been completed by the Statutory Auditors of the Company.
- As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".

Jyoti Prasad



4. The financial results for the quarter and half year ended 30th September, 2016 are also Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.

5. Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.

6. Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.

For, ISHITA DRUGS AND INDUSTRIES LIMITED

Jagdish Agrawal



Place	Ahmedabad	JAGDISH AGRAWAL
Date	13-Nov-17	MANAGING DIRECTOR DIN: 01031687

ISHITA DRUGS AND INDUSTRIES LIMITED
CIN: L24231GJ1992PLC017054
Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
Ahmedabad - 382170
Website: www.ishitadrugs.com
Contact: +91 9228016100

Statement of Assets and Liabilities

Amount in Rs.

Particulars	Half Year Ended		Previous Year Ended	
	6 Months Ended		12 Months Ended	
	Unaudited	Audited	Unaudited	Audited
	30-Sep-17		31-Mar-17	
ASSETS				
1 Non-current assets				
Property, plant and equipment	10257627		10171144	
Capital work-in-progress	0		0	
Investment property	0		0	
Goodwill	0		0	
Other intangible assets	0		0	
Intangible assets under development	0		0	
Biological assets other than bearer plants	0		0	
Investments accounted for using equity method	0		0	
Non-current financial assets				
Non-current investments	1592254		1592254	
Trade receivables, non-current	0		0	
Loans, non-current	0		498200	
Other non-current financial assets	0		0	
Total Non-current financial assets	1184981		1226158	
Deferred tax assets (net)	0		0	
Other non-current assets	0		0	
Total Non-current Assets	1184981		1226158	
2 Current assets				
Inventories	10661973		5616304	
Current financial assets				
Current investments	17061292		25361292	
Trade receivables, current	20342429		17040975	
Cash and cash equivalents	1124622		1174114	
Bank balance other than cash and cash equivalents	2757981		3051072	
Loans, current	1527892		89175	
Other current financial assets	8197829		7050239	
Total current financial assets	61674018		59383171	
Current tax assets (net)	0		0	
Other current assets	1594		0	
Total Current Assets	61675612		59383171	
3 Non-current assets classified as held for sale	0		0	
4 Regulatory deferral account debit balances and related deferred tax Assets	0		0	
TOTAL ASSETS	73525493.00		71644769.00	
EQUITIES AND LIABILITIES				
1 Equity				
Equity attributable to owners of Parent				
Equity share capital	29903000		29903000	
Other equity	29428930		28242900	
Total Equity attributable to owners of Parent	59331930.00		58145900.00	
Non controlling interest	0		0	
Total Equity	59331930.00		58145900.00	
2 Liabilities				
Non-current liabilities				
Non-current financial liabilities				
Borrowing, non-current	0		0	
Trade payables, non-current	0		0	
Other non-current financial liabilities	0		0	
Total Non-current financial liabilities	0.00		0.00	
Provisions, non-current	0		0	
Deferred tax liabilities (net)	639428		639428	
Deferred government grants, Non-current Other non-current liabilities	0		0	
Total Non-current liabilities	639428.00		639428.00	
Current liabilities				
Current financial liabilities				
Borrowing, current	1459378		72229	
Trade payables, current	9710776		11816720	
Other current financial liabilities	0		0	
Total current financial liabilities	11170154.00		11888949.00	
Other current liabilities	1646821		61652	
Provisions, current	1453883		908840	

Jaydevi Agrawal



	Current tax liabilities (Net)	-716723	0
	Deferred government grants, Current	0	0
	Total current liabilities	13554135.00	12859441.00
3	Liabilities directly associated with assets in disposal group classified as held for sale	0	0
4	Regulatory deferral account credit balances and related deferred tax liability	0	0
	Total Liabilities	14193563.00	13498869.00
	Total Equity and Liabilities	73525493.00	71644769.00

For, ISHITA DRUGS AND INDUSTRIES LIMITED

Jagdish Agrawal



Place	Ahmedabad	JAGDISH AGRAWAL
Date	13-Nov-17	MANAGING DIRECTOR
		DIN: 03031687